Safety and pharmacokinetics of GSK3494245, a highly selective Leishmaniasis kinetoplastid proteasome inhibitor for the treatment of visceral leishmaniasis: A Phase 1, randomized, single ascending dose escalation study in healthy participants.
来源：PubMed发布日期：2026-05-13作者：Moodley M, Kostapanos M, Iavarone L, Bracher M, Lavezzi SM0 次点击